RE:RE:5-year performance and all-time performancehopeforthebest, "The last 2 years are telling, stock value down MINUS 7.6% in 2021 and MINUS 3.3% in 2022."
Scoreboard:
Year-to-date: CZO up 12.9% S&P Biotech ETF +7.24% TSX-Venture 10.07%
One year: CZO up 40%. S&P Biotech ETF -5.14% TSX-Venture -25.55%
Two year: CZO up 1.45%. S&P Biotech ETF -42.8% TSX-Venture -34.09%
5 year: CZO up 6.06% S&P Biotech ETF -9.11% TSX-Venture -29.93%
CZO beats both the S&P Biotech ETF and the TSX-Venture in all categories. It has also posiitoned a top secret pipeline before key validation and catalysts.